Baxter is a global diversified healthcare company that develops products and therapies that aim to save and sustain the lives of people with hemophilia, kidney disease, immune disorders, and other chronic and acute conditions.
The company operates in three segments:
Develops plasma-based and recombinant proteins, plasma-based BioTherapeutics products, BioSurgery products and vaccines, and is investigating technologies for adult stem cell therapies.
Provides intravenous solutions and specialty products used for fluid replenishment, anesthesia, nutrition, pain management, antibiotic therapy and chemotherapy.
Develops products and services to treat end-stage kidney disease.
For more information please go to www.baxter.com
Baxter's BioScience business has been working in specialty biologic therapies for more than 75 years. The business pioneered protein therapies developed from the separation and purification of blood components, applying our knowledge and resources to become a leader in the treatment of immunodeficiencies, hemophilia and other blood-based disorders.
The BioScience business has a diversified portfolio and global expertise among many specialty therapeutic areas.
Baxter’s global biologics business is fully integrated and includes discovery, development, manufacturing and operations, and commercial businesses in the following areas:
A sterile, nonpyrogenic preparation of albumin in a single-dosage
Sterile, stable, lyophilized preparation of purified alpha 1-proteinase inhibitor
